Former Pfizer exec heads to Berlin Pharmaceutical Industry

> Berlin Pharmaceutical Industry, Thailand's leading manufacturer and marketer of generic pharmaceuticals, has named Amal Naj, a former senior VP at Pfizer, CEO and a member of the board. Release

> Vitae Pharmaceuticals today announced the appointment of Christine Brennan as chief business officer. Release

> Timothy Hayes, currently senior VP and region head for Bayer HealthCare's consumer care division in North America, will also lead the business unit's global business development function. Release

> Amneal Pharmaceuticals has tapped Shankar Hariharan as chief scientific officer/executive VP of specialty pharmaceuticals. Release

> Talecris Biotherapeutics has named Lafmin Morgan to its global commercial operations team as VP, U.S. product management.  Release

> Australia's Starpharma Holdings has appointed Malcolm McColl to join the company's existing business development team as a VP. Release

> Advaxis has hired Reshma Singh as a senior scientist. Release

> Columbia Laboratories has appointed G. Frederick Wilkinson, executive VP, global brands, of Watson Pharmaceuticals as a director of the company. His appointment brings to eight the number of members of Columbia's board. Release

> Vyteris has named four new members to its scientific advisory board--David Cohen, Robert Shorr, David Filer and Michael Reidy. Release

> K-V Pharmaceutical has announced the election of David Sidransky as a new independent member of the board of directors. Release

Suggested Articles

Preclinical-stage biotech Abpro Therapeutics wants to trial its two lead candidates for HER2-positive cancers and diabetic macular edema in 2019.

After a rough patch in 2017, the stars seem to be realigning for French CAR-T expert Cellectis, which just closed a $164 million U.S. public offering.

Investment firm Frazier Healthcare Partners has closed its 11th fund—worth $780 million—that will help established companies accelerate their growth.